These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CD28/PD1 co-expression: dual impact on CD8 Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752 [TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade-unresponsive human tumor-infiltrating CD8 Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901 [TBL] [Abstract][Full Text] [Related]
4. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028 [TBL] [Abstract][Full Text] [Related]
5. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT; Behera M; Wu H; McCausland M; Chen Z; Zhang C; Khuri FR; Owonikoko TK; Ahmed R; Ramalingam SS Proc Natl Acad Sci U S A; 2017 May; 114(19):4993-4998. PubMed ID: 28446615 [TBL] [Abstract][Full Text] [Related]
7. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy. Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468 [TBL] [Abstract][Full Text] [Related]
8. CD8 Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053 [TBL] [Abstract][Full Text] [Related]
9. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069 [TBL] [Abstract][Full Text] [Related]
10. A combined model of serum neutrophil extracellular traps, CD8 Guo J; Shu T; Zhang H; Huang N; Ren J; Lin L; Wu J; Wang Y; Huang Z; Bin J; Liao Y; Shi M; Liao W; Huang N FEBS J; 2024 Aug; 291(15):3403-3416. PubMed ID: 38661680 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy. Liu C; Jing W; An N; Li A; Yan W; Zhu H; Yu J J Transl Med; 2019 Oct; 17(1):344. PubMed ID: 31623615 [TBL] [Abstract][Full Text] [Related]
13. Dynamic changes in circulating PD-1 Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114 [TBL] [Abstract][Full Text] [Related]
14. TCR Repertoire Diversity of Peripheral PD-1 Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056 [TBL] [Abstract][Full Text] [Related]
15. Reversal of the CD8 Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C Front Immunol; 2021; 12():687296. PubMed ID: 34177939 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778 [TBL] [Abstract][Full Text] [Related]
18. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261 [TBL] [Abstract][Full Text] [Related]
19. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer. Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H Front Immunol; 2023; 14():1178193. PubMed ID: 37492578 [TBL] [Abstract][Full Text] [Related]
20. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC. Chen Y; Shao Z; Hao Z; Xin Z; Chen X; Huang L; Chen D; Lin M; Liu Q; Xu X; Li J; Wu D; Yan J; Chai Y; Wu P J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39134346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]